DepoVax (DPX-RSV) / BioVaxys - LARVOL DELTA

Evaluation of the protective potential of antibody and T cell responses elicited by a novel preventative vaccine towards respiratory syncytial virus small hydrophobic protein. (PubMed, Hum Vaccin Immunother) - "These findings show that older adults with clinically significant infection as well as vaccinated adults generate a humoral response to SHe. The induction of both SHe-specific antibody and cellular responses support further clinical development of the DPX-RSV(A) vaccine."

Journal

A Study to Evaluate the Safety and Reactogenicity of DPX-RSV(A), a Respiratory Syncytial Virus Vaccine (clinicaltrials.gov) - P1; N=40; Completed; Sponsor: Dalhousie University; Active, not recruiting ➔ Completed

Clinical • Trial completion

A Respiratory Syncytial Virus vaccine based on the Small Hydrophobic protein ectodomain presented with a novel lipid-based formulation is highly immunogenic and safe in adults: a first-in-humans study. (PubMed, J Infect Dis) - "This was a randomized, observer-blinded, first-in-humans study of a novel synthetic RSV antigen based on the ectodomain of the small hydrophobic glycoprotein (SHe) of RSV subgroup A, formulated with either the lipid and oil-based vaccine platform DepoVax (DPX-RSV[A]) or alum (RSV[A]-Alum), in healthy, 50-64-year-old individuals...Responses to Alum-adjuvanted vaccines were very low. A novel RSV antigen from the SH protein of RSV, formulated in a lipid and oil-based vaccine platform was highly immunogenic, with sustained antigen-specific antibody responses and had an acceptable safety profile."

Clinical • Journal • P1 data

A Study to Evaluate the Safety and Reactogenicity of DPX-RSV(A), a Respiratory Syncytial Virus Vaccine (clinicaltrials.gov) - P1; N=40; Active, not recruiting; Sponsor: Dalhousie University; Trial primary completion date: Jul 2018 ➔ Mar 2017

Clinical • Trial primary completion date